Lonza Group stock holds steady as 2025 sales and profit guide the story

Lonza Group (CH0013841017) is framed by its 2025 reporting base: sales of CHF 6.58 billion, core EBITDA of CHF 1.90 billion, and core EBITDA margin of 28.9% according to the companys investor materials. Those figures matter because they set the benchmark for the Swiss group’s 2026 comparison and for how investors read its operating leverage.

CHF 6.58 billion sets the base

Lonza said full-year 2025 sales reached CHF 6.58 billion, up 19.2% year on year on a reported basis, while core EBITDA rose to CHF 1.90 billion. The margin of 28.9% was supported by the companys mix and execution across its Pharma Biotech and Specialty Ingredients activities, with the 2025 numbers providing the clearest recent operating reference point.

The same reporting set shows core earnings per share of CHF 11.05 for 2025, compared with CHF 7.78 in the prior year. That gives a quantified comparison investors can use when checking whether later updates justify the valuation attached to the Swiss healthcare manufacturing group.

EPS rose to CHF 11.05

Lonza also reported core net income of CHF 884 million for 2025, compared with CHF 640 million in 2024. The move from CHF 640 million to CHF 884 million reinforces that the earnings base improved alongside sales and EBITDA, not just at the top line.

For market context, the stock trades on the SIX Swiss Exchange under the ticker SIX: LONN, and that venue matters because the share price and market capitalization are quoted in Swiss francs. The fact box below carries the latest quoted price context and market value if a live quote is available in the market data set used for publication.

Margin near 29%

Lonzas 2025 core EBITDA margin of 28.9% is the most compact summary of the year’s profitability. It sits well above a simple sales headline because it shows how much of every franc of revenue was retained after operating costs.

That margin also provides a useful bridge into the next reporting cycle. If 2026 updates show lower or higher profitability, the comparison will be against a clearly dated 2025 baseline rather than against an abstract long-term average.

Capsule manufacturing matters

A key representative business line is Lonzas capsule and health ingredients activity, which sits alongside its broader contract development and manufacturing work for pharma customers. The segment is relevant because Lonzas reported figures show how the mix of specialty and pharmaceutical work feeds through to sales and margin.

Swiss quote context

Lonza Group stock is anchored on the SIX Swiss Exchange and on the 2025 figures above: CHF 6.58 billion in sales, CHF 1.90 billion in core EBITDA, and CHF 11.05 in core EPS. If a current price is available in the market data used for publication, it should be matched to the same Swiss-franc quoting convention and kept consistent with the fact box.